Agalsidase beta
From Ganfyd
rINN: Agalsidase beta
Other Names
Agalsidase, Fabrazyme®, alpha-D- galactoside galactohydrolase, alpha-D-galactosidase A, alpha-galactosidase A precursor, melibiase
Pharmacological Information
Pharmacology Images
File:Agalsidase betaMolecule.png
Agalsidase beta Molecule
Web information on Agalsidase beta
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Agalsidase beta (Less technical, good quality control)
Wikipedia on Agalsidase beta (Less technical, ? quality control)
Contents |
Introduction
A recombinant human alpha-galactosidase A. (see also Agalsidase alpha)
Clinical Use
Indications
Administration
IV 1mg/kg body weight administered once every 2 weeks
Clinical Issues
IgG antibodies typically develop after 3 months. Immunologic tolerance can later develop.
Contra-indications
Cautions and Interactions
At some stage almost 70% have some form of (mild) reaction
Side effects
Special advice
Pharmacology
The mature glycosylated protein is composed of 2 subunits of 398 amino acids. Made in mammalian Chinese Hamster Ovary (CHO) cell culture.
